Darren Denjay Pan, MD, on Inflammatory Biomarkers as Predictors of Outcomes After CAR T-Cell Therapy for Multiple Myeloma

Posted: Monday, January 22, 2024

Darren Denjay Pan, MD, of Tisch Cancer Institute and the Icahn School of Medicine at Mount Sinai discusses key clinical questions raised by his findings that serologic biomarkers such as fibrinogen and ferritin might be valuable predictors of outcomes and toxicities for patients with multiple myeloma who are receiving CAR T-cell therapy.